News

High-yield dividend stocks can be a great way to build wealth over time. These stocks offer returns that often outperform the broader market, thanks to the power of compounding interest.

However

For a generic drugmaker like Viatris (NASDAQ: VTRS), big spurts of growth are unlikely. The market for low-cost generic medications is competitive, and success is largely defined by maintaining

No doubt about it, artificial intelligence (AI) is 2023's hottest tech trend. Beyond that, it's also helped power big gains for the stock market. Some analysts and industry watchers have already

A new month is here. And with it comes a new opportunity to invest in spectacular dividend stocks.

Three Motley Fool contributors think they know some great candidates to buy in July. Here's why

After a tough 2022, the stock market bounced back in the first half of 2023. The S&P 500 recorded a 16% gain through the end of June, while the tech-heavy Nasdaq Composite surged more than 31%

Drug companies Merck (NYSE: MRK) and AbbVie (NYSE: ABBV) have been two of the best pharmaceutical investments, easily delivering better total returns than the S&P 500 average over the past three

Tech stocks have generally done well this year, staging a solid recovery from a tough 2022. But not all tech stocks are created equal. AT&T (NYSE: T) looks like a bargain, while Apple (NASDAQ: AAPL)

Temperatures are rising. And so are concerns about what's next for the stock market. The answer to the former issue is air conditioning and/or a cool swim. The latter is more challenging.

However

Vertex Pharmaceuticals (NASDAQ: VRTX) is heading toward a big moment: a regulatory decision on what may become its next game-changing product. And this potential product, exa-cel for blood

Epcoritamab, a cancer drug co-developed by AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB), was recently given the green light by the Food and Drug Administration to be used as a treatment for adults

Over the past decade, few stocks have been as much of a disappointment as AT&T (NYSE: T). As you can see from the chart below, the stock price has fallen 41% during that time, even though it's

Shares in Pfizer (NYSE: PFE) were falling recently after it discontinued clinical trials for a potential diabetes and weight-loss therapy. The drop was due to negative perceptions after lotiglipron

On June 26, FibroGen's (NASDAQ: FGEN) lead program, pamrevlumab, reported poor late-stage clinical trial results for the second time in a month, sending its stock barreling downward to the tune of

On June 26, Pfizer (NYSE: PFE) gave investors an update that they probably didn't like. One of its two candidates for treating diabetes and obesity, called lotiglipron, will not be developed any

Shares of biosimilar pharmaceutical maker Alvotech (NASDAQ: ALVO) were up more than 11% as of noon on Friday. On Thursday, it plunged more than 6% after the company announced it had received a

Shares of CymaBay Therapeutics (NASDAQ: CBAY) were up more than 37% as of 11:15 a.m. ET on Friday. The clinical-stage biotech saw its shares rise after Ipsen and Genfit announced phase 3 trials data

Things have not quite gone as hoped lately for shares of Sarepta Therapeutics (NASDAQ: SRPT). Recently, the biotech received approval from the Food and Drug Administration (FDA) for its cutting-edge

Shares of Opko Health (NASDAQ: OPK) were up more than 11% around 2:30 p.m. ET on Thursday. The healthcare company announced after the markets closed on Wednesday that a treatment for pediatric

Biotech heavyweight Amgen (NASDAQ: AMGN) will probably continue to be an active player in the merger and acquisition (M&A) scene, regardless of what happens with its proposed $28 billion buyout of

Shares of CorMedix (NASDAQ: CRMD) were down more than 21% as of noon ET on Thursday. The shares fell after the company announced a stock sale. The healthcare stock is down more than 5% so far this